Gencor Industries Company Profile (NASDAQ:GENC)

About Gencor Industries

Gencor Industries logoGencor Industries, Inc. is a manufacturer of heavy machinery used in the production of highway construction materials, synthetic fuels, and environmental control equipment. The Company designs, manufactures, and sells machinery and related equipment used for the production of asphalt and highway construction materials. The Company's products include asphalt plants, combustion systems and fluid heat transfer systems. The Company's products are manufactured in approximately two facilities in the United States. The Company manufactures and produces hot-mix asphalt plants used in the production of asphalt paving materials. The Company manufactures related asphalt plant equipment, including hot mix storage silos, fabric filtration systems, cold feed bins and other plant components. The Company also manufactures Combustion Systems and Industrial Incinerators, and Fluid Heat Transfer Systems.

Industry, Sector and Symbol:
  • Sector: Industrial Products
  • Industry: Farm & Construction Machinery
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GENC
  • CUSIP:
Key Metrics:
  • Previous Close: $11.66
  • 50 Day Moving Average: $11.58
  • 200 Day Moving Average: $10.40
  • 52-Week Range: $14,336,000.00 - $5.95
  • Trailing P/E Ratio: 53.73
  • Foreward P/E Ratio: 29.15
  • P/E Growth: 0.00
  • Market Cap: $167.16M
  • Outstanding Shares: 14,336,000
  • Beta: 0.41
  • Net Margins: 4.86%
  • Return on Equity: 2.68%
  • Return on Assets: 2.49%
  • Current Ratio: 15.68%
  • Quick Ratio: 14.17%
Additional Links:
Companies Related to Gencor Industries:

Analyst Ratings

Consensus Ratings for Gencor Industries (NASDAQ:GENC) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Gencor Industries (NASDAQ:GENC)
No equities research coverage for this company has been tracked by


Earnings History for Gencor Industries (NASDAQ:GENC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/9/2014$0.06($0.06)ViewN/AView Earnings Details
8/5/2014$0.14$0.17ViewN/AView Earnings Details
2/7/2014Q1 14$0.05ViewN/AView Earnings Details
12/13/2013Q4$0.24ViewN/AView Earnings Details
2/11/2013Q1 2013($0.10)$6.90 million$4.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Gencor Industries (NASDAQ:GENC)
Current Year EPS Consensus Estimate: $0.34 EPS
Next Year EPS Consensus Estimate: $0.40 EPS


Dividend History for Gencor Industries (NASDAQ:GENC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Gencor Industries (NASDAQ:GENC)
Insider Ownership Percentage: 31.87%
Institutional Ownership Percentage: 15.71%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2016Lawrence MaingotVPSell1,500$12.00$18,000.00View SEC Filing  
8/17/2016Eric E MellenCFOBuy10,000$10.75$107,500.00View SEC Filing  
7/27/2016Sherry HoutkinMajor ShareholderSell4,718$17.91$84,499.38View SEC Filing  
7/26/2016Sherry HoutkinMajor ShareholderSell7,000$17.31$121,170.00View SEC Filing  
7/22/2016Sherry HoutkinMajor ShareholderSell2,000$16.88$33,760.00View SEC Filing  
7/21/2016Sherry HoutkinMajor ShareholderSell10,000$16.85$168,500.00View SEC Filing  
7/19/2016Sherry HoutkinMajor ShareholderSell6,000$16.87$101,220.00View SEC Filing  
7/15/2016Sherry HoutkinMajor ShareholderSell13,541$16.74$226,676.34View SEC Filing  
7/13/2016Sherry HoutkinMajor ShareholderSell15,000$16.00$240,000.00View SEC Filing  
7/12/2016Sherry HoutkinMajor ShareholderSell5,000$15.51$77,550.00View SEC Filing  
7/11/2016Sherry HoutkinMajor ShareholderSell10,251$15.26$156,430.26View SEC Filing  
7/7/2016Sherry HoutkinMajor ShareholderSell11,890$15.07$179,182.30View SEC Filing  
6/7/2016Marc G ElliottPresidentSell15,000$14.91$223,650.00View SEC Filing  
6/3/2016Marc G ElliottPresidentSell2,000$14.74$29,480.00View SEC Filing  
5/16/2016Marc G ElliottPresidentSell24,000$14.86$356,640.00View SEC Filing  
3/3/2016David AirDirectorSell5,000$13.40$67,000.00View SEC Filing  
3/2/2016Sherry HoutkinMajor ShareholderSell10,000$13.38$133,800.00View SEC Filing  
3/1/2016Sherry HoutkinMajor ShareholderSell20,000$13.54$270,800.00View SEC Filing  
2/26/2016Sherry HoutkinMajor ShareholderSell50,000$13.11$655,500.00View SEC Filing  
2/17/2016Marc G. ElliottPresidentSell9,140$12.68$115,895.20View SEC Filing  
12/15/2015Marc G. ElliottPresidentSell19,044$12.74$242,620.56View SEC Filing  
10/6/2015Sherry HoutkinMajor ShareholderSell80,000$9.26$740,800.00View SEC Filing  
5/6/2015Sherry HoutkinMajor ShareholderSell70,000$9.20$644,000.00View SEC Filing  
12/8/2014Sherry HoutkinMajor ShareholderSell2,948$9.72$28,654.56View SEC Filing  
12/2/2014Sherry HoutkinMajor ShareholderSell5,000$9.93$49,650.00View SEC Filing  
11/25/2014Sherry HoutkinMajor ShareholderSell200,000$9.25$1,850,000.00View SEC Filing  
9/2/2014Sherry HoutkinMajor ShareholderSell5,000$10.18$50,900.00View SEC Filing  
8/26/2014Sherry HoutkinMajor ShareholderSell5,346$10.23$54,689.58View SEC Filing  
8/25/2014Sherry HoutkinMajor ShareholderSell344$10.20$3,508.80View SEC Filing  
8/21/2014Sherry HoutkinMajor ShareholderSell4,984$10.18$50,737.12View SEC Filing  
8/20/2014Sherry HoutkinMajor ShareholderSell2,200$10.16$22,352.00View SEC Filing  
8/19/2014Sherry HoutkinMajor ShareholderSell1,208$10.20$12,321.60View SEC Filing  
3/11/2014Jeanne M LyonsInsiderSell1,500$10.93$16,395.00View SEC Filing  
2/20/2014Jeanne M LyonsInsiderSell2,000$10.97$21,940.00View SEC Filing  
2/19/2014Eric E MellenCFOSell11,051$11.07$122,334.57View SEC Filing  
10/14/2013Sherry HoutkinMajor ShareholderSell80,086$8.80$704,756.80View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Gencor Industries (NASDAQ:GENC)
DateHeadline logoGenmab Announces U.S. FDA Approval of Arzerra® (ofatumumab) in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL (NASDAQ:GENC) - August 31 at 9:54 AM logoData from Phase III CASTOR Study of Daratumumab Published in The New England Journal of Medicine (NASDAQ:GENC) - August 25 at 10:12 AM logoGenmab Announces European Regulatory Submission for Daratumumab in Relapsed Multiple Myeloma (NASDAQ:GENC) - August 23 at 9:32 AM logoArticles of Association for Genmab A/S (NASDAQ:GENC) - August 18 at 5:13 PM logoTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (NASDAQ:GENC) - August 17 at 5:26 PM logoGENCOR INDUSTRIES INC Financials (NASDAQ:GENC) - August 17 at 5:26 PM logoGenmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Relapsed Multiple Myeloma (NASDAQ:GENC) - August 17 at 5:26 PM logoETF’s with exposure to Gencor Industries, Inc. : August 16, 2016 (NASDAQ:GENC) - August 16 at 5:21 PM logoGencor Industries, Inc. :GENC-US: Earnings Analysis: Q3, 2016 By the Numbers : August 12, 2016 (NASDAQ:GENC) - August 12 at 5:15 PM logoGenmab Enters Commercial License Agreement with Gilead for DuoBody® Technology (NASDAQ:GENC) - August 10 at 5:26 PM
News IconGencor Sales Up 82.6% in 3Q (NASDAQ:GENC) - August 9 at 9:32 PM logoGencor Releases Third Quarter Fiscal 2016 Results (NASDAQ:GENC) - August 9 at 9:32 PM logoGencor posts 3Q profit (NASDAQ:GENC) - August 9 at 3:56 PM logoGenmab Announces Financial Results for the First Half of 2016 and Improves 2016 Financial Guidance (NASDAQ:GENC) - August 9 at 3:56 PM logoGenmab Appoints Board Observer (NASDAQ:GENC) - August 3 at 8:07 AM logoDaratumumab Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration in Combination with Standard of Care Regimens for Previously Treated Multiple Myeloma (NASDAQ:GENC) - July 25 at 8:18 PM logoSplits Calendar: Gencor Industries splits before market open today (3:2 ratio) (NASDAQ:GENC) - July 22 at 7:03 AM logoETF’s with exposure to Gencor Industries, Inc. : July 18, 2016 (NASDAQ:GENC) - July 18 at 1:49 PM logoCSE: 2016-0704 - Delist - GoviEx Uranium Inc. (GXU) (NASDAQ:GENC) - July 12 at 9:36 AM logoGENCOR INDUSTRIES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:GENC) - July 11 at 3:20 PM logo10:17 am Gencor Industries announces a 3:2 stock split on class B shares in the form of a 50% dividend, ex split date is Aug 1 (NASDAQ:GENC) - July 11 at 10:17 AM logoGencor Announces 50% Stock Dividend (NASDAQ:GENC) - July 11 at 10:14 AM logoETF’s with exposure to Gencor Industries, Inc. : July 7, 2016 (NASDAQ:GENC) - July 7 at 2:56 PM logoGenmab Provides Update on Marketing Authorization Application for Arzerra® (ofatumumab) as Maintenance Therapy for Patients with Relapsed CLL (NASDAQ:GENC) - June 23 at 10:29 AM logoGrant of Warrants to Genmab Employees (NASDAQ:GENC) - June 9 at 12:59 PM logoGencor Industries, Inc. :GENC-US: Earnings Analysis: Q2, 2016 By the Numbers : June 8, 2016 (NASDAQ:GENC) - June 8 at 9:45 AM logoGenmab's Total Number of Voting Rights and Total Share Capital (NASDAQ:GENC) - May 31 at 11:12 AM logoGenmab to Present at the Goldman Sachs 37th Annual Global Healthcare Conference (NASDAQ:GENC) - May 31 at 3:22 AM logoGenmab Achieves USD 30 Million Milestone in DARZALEX® (daratumumab) Collaboration with Janssen (NASDAQ:GENC) - May 30 at 11:10 AM logoGenmab Achieves USD 30 Million Milestone in DARZALEX® (daratumumab) Collaboration with Janssen (NASDAQ:GENC) - May 30 at 11:10 AM logoGenmab Announces European Conditional Marketing Authorization for DARZALEX® (daratumumab) for Multiple Myeloma (NASDAQ:GENC) - May 23 at 6:56 AM logoFirst Participants Dosed in Clinical Study with DuoBody® Product (NASDAQ:GENC) - May 20 at 3:33 AM logoDaratumumab and Ofatumumab Data to Be Presented at 21st Congress of EHA (NASDAQ:GENC) - May 19 at 7:22 AM logoGenmab Announces Positive Topline Result in Phase III POLLUX Study of Daratumumab in Relapsed or Refractory Multiple Myeloma (NASDAQ:GENC) - May 18 at 2:32 PM logoCapital Increase in Genmab as a Result of Employee Warrant Exercise (NASDAQ:GENC) - May 18 at 12:02 PM logoOfatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL accepted for priority review by FDA (NASDAQ:GENC) - May 17 at 4:12 PM logoGenmab Announces Financial Results for the First Quarter of 2016 (NASDAQ:GENC) - May 10 at 11:18 AM logoGencor posts 2Q profit (NASDAQ:GENC) - May 9 at 7:36 PM logoGencor Releases Second Quarter Fiscal 2016 Results (NASDAQ:GENC) - May 9 at 4:30 PM
News IconGencor Industries Incorporated (NASDAQ:GENC) Sellers Covered 29.52% of Their Shorts (NASDAQ:GENC) - April 22 at 10:59 AM logoGenmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting (NASDAQ:GENC) - April 20 at 10:51 AM logoGenmab Updates Financial Guidance for 2016 (NASDAQ:GENC) - April 20 at 1:12 AM logoGencor Industries Inc. (GENC) (NASDAQ:GENC) - April 15 at 2:06 PM logoETF’s with exposure to Gencor Industries, Inc. : April 8, 2016 (NASDAQ:GENC) - April 8 at 5:35 PM logoGencor Industries, Inc. :GENC-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:GENC) - April 7 at 10:13 AM logoPatent Infringement Lawsuit Filed Against Genmab and Janssen in the United States Regarding DARZALEX® (NASDAQ:GENC) - April 4 at 2:05 PM logoCHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Relapsed and Refractory Multiple Myeloma (NASDAQ:GENC) - April 1 at 11:41 AM logoGenmab Announces Positive Interim Result in Phase III Castor Study of Daratumumab in Relapsed or Refractory Multiple Myeloma (NASDAQ:GENC) - March 30 at 12:21 PM logoGENCOR INDUSTRIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:GENC) - March 10 at 5:01 PM logoInsider Trading Alert - GENC, LPLA And RMD Traded By Insiders (NASDAQ:GENC) - March 5 at 2:39 PM


Gencor Industries (NASDAQ:GENC) Chart for Monday, September, 26, 2016

Last Updated on 9/26/2016 by Staff